Quick Answer ABVC BIOPHARMA, INC. reported Net Income of -$7.91 million for fiscal year 2025. ABVC BIOPHARMA, INC. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$7.91M -61.3% 2024 -$4.90M +37.0% 2023 -$7.79M +52.6% 2022 -$16.42M -27.9% 2021 -$12.84M -21.2% 2020 -$10.59M -169.3% 2019 -$3.93M +35.1% 2018 -$6.06M -42.9% 2017 -$4.24M … Read more
Quick Answer ABVC BIOPHARMA, INC. reported Total Revenue of $509.6 thousand for fiscal year 2024. ABVC BIOPHARMA, INC. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2024 $509.6K +234.3% 2023 $152.4K -84.3% 2022 $969.8K +172.6% 2021 $355.8K -26.3% 2020 $483.0K -31.2% 2019 $701.7K +9988.0% 2018 $7.0K +107.0% 2015 $3.4K — 2014 $0.00 … Read more
Quick Answer ABVC BIOPHARMA, INC. reported Total Revenue of $509.6 thousand for fiscal year 2024. ABVC BIOPHARMA, INC. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue — $509.6K+234.3% $152.4K-84.3% $969.8K+172.6% $355.8K-26.3% $483.0K-31.2% Net Income -$7.91M-61.3% -$4.90M+37.0% -$7.79M+52.6% -$16.42M-27.9% -$12.84M-21.2% -$10.59M-169.3% Diluted EPS -$0.39+7.1% -$0.42+76.7% -$1.80+65.3% -$5.19-917.6% -$0.51 — Total … Read more
Quick Answer Arbutus Biopharma Corp reported Shares Outstanding of 192.53 million shares for fiscal year 2025. Arbutus Biopharma Corp Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 192.53M +1.4% 2024 189.96M +11.8% 2023 169.87M +7.9% 2022 157.46M +8.6% 2021 144.99M +61.7% 2020 89.68M +38.4% 2019 64.78M +16.7% 2018 55.52M +0.8% 2017 … Read more
Quick Answer Arbutus Biopharma Corp reported Operating Income of -$38.16 million for fiscal year 2025. Arbutus Biopharma Corp Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$38.16M +50.0% 2024 -$76.32M +2.3% 2023 -$78.10M -19.3% 2022 -$65.46M +11.0% 2021 -$73.52M -27.2% 2020 -$57.81M +59.8% 2019 -$143.90M -60.3% 2018 -$89.78M +19.1% 2017 -$110.93M … Read more
Quick Answer Arbutus Biopharma Corp reported R&D Expense of $25.24 million for fiscal year 2025. Arbutus Biopharma Corp R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $25.24M -53.3% 2024 $54.04M -26.7% 2023 $73.70M -12.7% 2022 $84.41M +28.9% 2021 $65.50M +32.8% 2020 $49.34M -14.3% 2019 $57.60M -0.6% 2018 $57.93M -7.6% 2017 $62.68M … Read more
Quick Answer Arbutus Biopharma Corp reported Stockholders Equity of $76.58 million for fiscal year 2025. Arbutus Biopharma Corp Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $76.58M -21.4% 2024 $97.37M -8.2% 2023 $106.02M -22.5% 2022 $136.85M -19.2% 2021 $169.44M +66.2% 2020 $101.97M +40.2% 2019 $72.74M -63.7% 2018 $200.23M +9.7% 2017 $182.47M … Read more
Quick Answer Arbutus Biopharma Corp reported Cash and Equivalents of $18.01 million for fiscal year 2025. Arbutus Biopharma Corp Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $18.01M -50.4% 2024 $36.33M +38.2% 2023 $26.29M -14.6% 2022 $30.78M -71.8% 2021 $109.28M +109.1% 2020 $52.25M +64.3% 2019 $31.80M -13.9% 2018 $36.94M … Read more
Quick Answer Arbutus Biopharma Corp reported Total Assets of $94.62 million for fiscal year 2025. Arbutus Biopharma Corp Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $94.62M -28.2% 2024 $131.71M -8.8% 2023 $144.40M -26.1% 2022 $195.42M -4.4% 2021 $204.49M +49.2% 2020 $137.08M +29.9% 2019 $105.53M -53.7% 2018 $227.91M -3.9% 2017 $237.16M … Read more
Quick Answer Arbutus Biopharma Corp reported Net Income of -$33.50 million for fiscal year 2025. Arbutus Biopharma Corp Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$33.50M +52.1% 2024 -$69.92M +4.0% 2023 -$72.85M -4.9% 2022 -$69.46M +8.9% 2021 -$76.25M -19.6% 2020 -$63.74M +58.5% 2019 -$153.72M -169.4% 2018 -$57.06M +32.4% 2017 -$84.41M … Read more